Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On March16, 2017, Karyopharm Therapeutics Inc. (the Company)
issued a press release regarding its financial results for the
quarter and fiscal year ended December31, 2016 and will conduct a
previously-announced, publicly available conference call to
discuss those results. The full text of the press release issued
in connection with the announcement is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by
reference.
The information provided under this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:
99.1 Press release issued by Karyopharm Therapeutics Inc. on
March16, 2017.
About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Recent Trading Information
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) closed its last trading session up +0.04 at 10.04 with 239,065 shares trading hands.